MDxHealth

NEWS RELEASE

MDxHealth Licenses Biomarkers for Bladder Cancer to Predictive Biosciences

DURHAM, NC, LIEGE, BELGIUM and LEXINGTON, MA – November 22nd, 2010 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has agreed to out-license certain DNA methylation biomarkers to Predictive Biosciences (Lexington, MA) for diagnostic applications in bladder cancer.

Under the agreement, MDxHealth grants Predictive Biosciences exclusive rights for the use of a number of its DNA methylation biomarkers in bladder cancer testing in the United States. MDxHealth retains exclusive worldwide rights to these markers in tissue-based bladder cancer tests. In return, MDxHealth will receive upfront and milestone payments and royalties on net sales. Predictive Biosciences is one of the few diagnostic companies with a strong focus on applications in urologic oncology, including bladder cancer.

"We are pleased to work with Predictive Biosciences, a recognized player in the urologic oncology space, just like our partner Exact Sciences is in colon cancer screening. We believe that collaborating with partners who focus on one specific disease area is a better way to leverage our biomarkers for cancer screening as these dedicated companies stand a greater chance of bringing these products successfully to market," said Dr. Jan Groen, Chief Executive Officer of MDxHealth.

"Predictive Biosciences is delighted to obtain an exclusive license to MDxHealth's proprietary DNA methylation biomarkers for use in our bladder cancer programs. These powerful biomarkers can play an important role in rapidly developing an industry-leading diagnostic panel for the management of bladder cancer, a devastating disease for which today physicians have only limited tools at their disposal," said Peter Klemm, Chief Executive Officer of Predictive Biosciences.

About MDxHealth
MDxHealth™ is a leading molecular diagnostics company that develops and commercializes oncology based molecular diagnostic testing for personalized medicine. The company's tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research centers such as Johns Hopkins University, Duke University, Lovelace Respiratory Research Institute, Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan Kettering and major European medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering-Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Qiagen and other industry leaders.

About Predictive Biosciences
Predictive Biosciences is a fully - integrated developer of novel molecular diagnostic cancer assays and an urology - focused provider of anatomic pathology laboratory products and services. Leveraging a portfolio of patented biomarkers and clinical approaches, the company is building a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. Predictive Biosciences' commercial division, OncoDiagnostic Laboratory (ODL), is a Clinical Laboratory Improvement Act (CLIA) - certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists and other subspecialty physicians. For additional information, please visit www.predictivebiosci.com.

For more information:

Dr. Jan Groen, CEO
MDxHealth
+32 4.364.20.70
IR@MDxHealth.com

Hans Herklots
Capricorn One
+41 79 598 7149

Dr. Andy Hu
Predictive Biosciences
+1 (781) 402-1780 x202
ahu@predictivebiosci.com

Sharon Bleakney
Predictive Biosciences
 +1 (781) 402-1780 x246
sbleakney@predictivebiosci.com